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ABSTRACT
OBJECTIVE: To analyze the risks related to vaccines and the impacts of non-vaccination on 
the world population.
METHODS: This is a narrative review that has considered information present in the 
bibliographic databases NCBI-PubMed, Medline, Lilacs, and Scientific Electronic Library Online 
(SciELO), between November 2015 and November 2016. For the analysis of outbreaks caused by 
non-vaccination, we considered the work published between 2010 and 2016.
RESULTS: We have described the main components of the vaccines offered by the Brazilian 
public health system and the adverse events associated with these elements. Except for local 
inflammatory reactions and rare events, such as exacerbation of autoimmune diseases and 
allergies, no causal relationship has been demonstrated between the administration of vaccines 
and autism, Alzheimer’s disease, or narcolepsy. On the other hand, the lack of information and the 
dissemination of non-scientific information have contributed to the reemergence of infectious 
diseases in several countries in the world and they jeopardize global plans for the eradication 
of these diseases. 
CONCLUSIONS: The population should be well informed about the benefits of vaccination and 
health professionals should assume the role of disseminating truthful information with scientific 
support on the subject, as an ethical and professional commitment to society.
DESCRIPTORS: Vaccination, utilization. Vaccination, adverse effects. Vaccines. Immunization. 
Adjuvants, Immunologic, contraindications. Risk Factors. Communicable Disease Control. 
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INTRODUCTION
The first vaccine was discovered by Edward Jenner in 1796, after 20 years of studies and 
experiments with cowpox, giving rise to the terms vaccine and vaccination (derived from 
the Latin term for cow, vacca). In eighteenth-century England, smallpox accounted for 
approximately 10% of total deaths, and one-third of these deaths were among children. 
Classified as one of the most devastating diseases in the history of mankind, smallpox was 
considered eradicated by the World Health Organization (WHO) in 1980, following the 
implementation of a world-wide mass vaccination program1.
Despite the notable relevance in eradicating or controlling various infectious diseases, 
vaccines are often related to questioning and criticism about the adverse effects. They have 
also been involved in some tragic events in the pharmaceutical industry. The biggest one 
occurred in 1955, after failure in the manufacturing process of the inactivated poliomyelitis 
vaccine2. Other episodes were recorded involving specific components of the BCG (Bacillus 
Calmette-Guérin), MMR (measles, mumps, and rubella), rotavirus3, oral polio4, and cell 
pertussis5 vaccines. Because of such events, efforts have been made to ensure greater safety 
in the manufacture and use of vaccines and they have definitely solved problems such as 
those mentioned above. The inactivated formulation (known as Salk or IPV) is currently 
administered in children up to four months. Because they contain dead viruses, they avoid 
the serious adverse effects observed with the attenuated virus formulation (OPV). Another 
example is the pertussis vaccine (present in the DTaP vaccine – diphtheria, tetanus, and 
acellular pertussis), which has undergone modifications to replace the cell pertussis vaccine, 
related to serious adverse events in the 1970s6.
The creation of the National Immunization Program (PNI), in 1973, by determination of the 
Ministry of Health was a major step for the public health in Brazil. Currently, 19 vaccines 
recommended by the WHO are offered free of charge in the Brazilian Unified Health 
System (SUS) and they benefit all age groups, following a national vaccination schedule7. 
In order to coordinate immunization actions, the program ensured the continuity of doses 
(compliance with schedule) and expanded the coverage area in Brazil8, reaching averages 
above 95% of vaccine coverage for the immunization schedule of children9. Some important 
results are the elimination of poliomyelitis and the sustained transmission of measles and 
rubella in the country9. 
However, despite the impact on reducing cases and deaths from vaccine-preventable diseases, 
anti-vaccination movements are increasingly frequent and persuasive. These movements use 
strategies such as distortion and dissemination of false information that, claiming to have 
a scientific basis, question the efficacy and safety of various vaccines10. Most of them relate 
vaccines, such as the MMR, adjuvants, and the thimerosal preservative to the occurrence of 
autism in children. A temporal association is sought, mainly because the disease is diagnosed 
after the application of most vaccines present in the immunization schedule of the child, 
without necessarily having a causal relationship. Another example of an association without 
a causal relationship recently reported in the media was the occurrence of cases of temporary 
paralysis following immunization with the human papillomavirus (HPV) vaccine. 
Vaccines are rigorously tested and monitored by their manufacturers and the health systems 
of the countries where they are applied. The licensing and marketing of vaccines occur only 
after approval by specific regulatory agencies and careful, costly, and time-consuming clinical 
trials (phase I, II, and III) with accredited volunteers. Phase IV occurs only after approval 
of the commercialization of the product and its main objective is to detect adverse events 
not registered in the previous phases, the so-called Adverse Events Following Immunization 
(AEFI). The WHO recommended the surveillance of AEFI in 1991, and the National System 
for the Surveillance of Adverse Events Following Immunization (VEAPV) was structured 
in Brazil in 1992. In addition, the National Institute for Quality Control in Health (INCQS), 
directly linked to the National Health Surveillance System, ensures the quality of the 
immunobiologicals distributed, whose rejection rates are less than 1%4. 
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A quick search with the term “anti-vaccination” in one of the largest social networks currently 
used pointed to 20 pages and 17 groups related to anti-vaccination movements, with almost 
15,000 followers in one of them. The same term was applied to the largest web search engine, 
which had more than six million results, including blogs and communities that support 
non-vaccination. This shows the need to clarify the population about the importance of 
vaccines and the danger posed by non-vaccination. 
This study aimed to evaluate the possible risks associated with the vaccines in use in Brazil. 
METHODS
This is a study based on literature searches on the investigation of the risks associated 
with vaccination and outbreaks triggered by the practice of non-vaccination and related 
subjects. This is a narrative review, which considered information present in the following 
bibliographic databases: PubMed, Medline, Lilacs, and Scientific Electronic Library Online 
(SciELO). Regarding the investigation of the risks associated with vaccines and their 
components, the search was carried out between November 2015 and November 2016 using 
the descriptors: PVAE, adverse events, vaccine, vaccination, and terms related to a disease, 
vaccine, or specific component, such as autism, syndrome, HPV vaccine, MMR vaccine, 
thimerosal. The same terms, in Portuguese, were also used: “AEFI”, “eventos adversos”, “vacina”, 
“vacinação”, “autismo”, “síndrome”, “vacina de HPV”, “vacina tríplice viral”, “timerosal”. For the 
analysis of outbreaks caused by non-vaccination, we searched the NCBI-PubMed platform 
with terms related to diseases with available vaccination, for example measles and mumps, 
added to the terms “outbreak” and “unvaccinated”. The results were selected after reading 
the summary of the articles and we considered only articles that showed a clear relation 
between non-vaccination events and outbreaks or epidemics of the disease, published 
between 2010 and 2016. We carried out a survey on the subject using the terms “anti-vaccine 
movement”, “vaccine hesitancy”, “vaccine refusal”, and “non-vaccination” added or not to the 
term “outbreak”. We excluded articles, letters, abstracts, or dissertations in other languages 
besides Portuguese, English, or Spanish. 
RESULTS
Risks Associated with Immunization 
Most of the news linked in informal social media and some published works have presented or 
suggested autism or Autism Spectrum Disorder (ASD) as one of the main diseases attributed 
to the practice of vaccination, mainly for the measles, mumps, and rubella (MMR) vaccine. 
However, the Brazilian Health Surveillance Agency (ANVISA), as well as the American Food 
and Drug Administration (FDA) have not shown any association between vaccines and the 
increase of cases of autism in the population2,11–13.
Adjuvants, often found in vaccine formulations, may also be associated with the onset of 
adverse reactions and events. Among the adjuvants used in the production of vaccines, we 
can mention mineral salts (aluminum salts and calcium salts), microbial derivatives such as, 
Monophosphoryl Lipid A (MPL) and oil-in-water emulsions using squalene as main compound 
(AS03 and MF59)14. The administration of these compounds may lead to adverse reactions8, 
such as local inflammatory reactions and, much less frequently, systemic effects, such as the 
exacerbation of autoimmune diseases and allergies. In addition, other diseases have been 
investigated regarding the causal relationship with adjuvants15. We highlight the reactions to 
aluminum salts, such as allergies and ASIA (Autoimmune/Inflammatory Syndrome Induced 
by Adjuvants)15,16, macrophagic myofasciitis15,17, and neurological diseases, such as Alzheimer18 
and syndromes included in the ASD18. However, no correlation has been reported in the 
scientific analyses for any of them. In addition to aluminum salts, we also highlight diseases 
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related to squalene, present in the pandemic and seasonal influenza vaccines, such as Gulf 
War Syndrome15,18 and Narcolepsy19,20 (Table 1), but no causal relationship has been found. 
In addition to the adjuvants, other vaccine components, such as stabilizers and preservatives, 
may be related to different adverse events (Table 1). The main examples are: albumin and gelatin 
(proteins used as stabilizers); antibiotics, commonly used during the early stages of vaccine 
preparation and often associated with allergic reactions; and formaldehyde, which in liquid 
form, is used in the initial stages of some vaccines as an inactivating agent for toxins or viral 
particles. Formaldehyde has been linked to some adverse events such as eczema and even cancer. 
However, studies evaluating the association of cancer with the use of formaldehyde have proved 
the association after exposure to large amounts or frequent exposure, that is, under conditions 
that do not apply to vaccines29,30. Egg proteins may also be present in very low amounts in some 
vaccines that use viruses grown in embryonated eggs, such as the influenza vaccine. These 
proteins may trigger an allergic response in persons intolerant to this component31,32.
Used as a preservative in some licensed vaccines, thimerosal is an organic compound based 
on mercury that has also been involved in controversial issues about vaccine safety. The 
association between autism, mercury, and vaccines came with the publication of a paper 
in 1998 by the English physician Andrew Wakefield in one of the most important scientific 
journals33. In this study, the authors pointed out symptoms, such as intestinal disorders and 
developmental delay in twelve children evaluated, and behavioral changes (including autism) 
in nine of them. In 2010, after a court decision, the article was fully removed after it was 
discovered the presence of false information in the study34, as well as payment agreements 
involving the researcher and attorneys in compensation cases for vaccine damages. Some 
studies have also shown that the dose of mercury normally ingested by an individual in the 
diet is much higher than the amount present in vaccines35–38. To date, no regulatory agency 
has actually proved the association between these diseases and the preservative.
In general, the occurrence of hypersensitivity reactions depends on the susceptibility, which 
makes the individual predisposed to its occurrence. Thus, the administration of certain 
vaccines is contraindicated in patients with a history of anaphylactic reaction to milk, eggs, 
or any other component that is present in a particular formulation. There is also evidence 
that some adverse events are the result of genetic factors, such as influenza vaccine-related 
narcolepsy (with squalene and alpha-tocopherol as adjuvant). Other adverse events are 
considered as idiosyncratic, that is, dependent on individual factors8.
Table 1. Adverse events associated with the use of vaccine adjuvants.
Adjuvant Vaccine Adverse events studied References
Aluminum salts
DPT
Pentavalent
Hepatitis A and B
Meningococcal
Macrophagic myofasciitis,
Alzheimer, and ASD
17,21
HPV
Postural Orthostatic Tachycardia 
Syndrome (POTS),
Guillain-Barré Syndrome (GBS)
22–25
Squalene – MF59
HIV; Herpes zoster; Cytomegalovirus; 
Influenza
Gulf War Syndrome 8,26
Squalene – AS03 Influenza
Narcolepsy
Paresthesia
8,27,28
DPT: diphtheria, tetanus, and pertussis; HPV: human papillomavirus; ASD: Autism Spectrum Disorder
5Adverse events of vaccines and non-vaccination Aps LRMM et al.
https://doi.org/10.11606/S1518-8787.2018052000384
Recently, prophylactic vaccines against HPV infection gained space in the media for possible 
involvement with the Guillain-Barré Syndrome (GBS) and Postural Orthostatic Tachycardia 
Syndrome (POTS). The GBS is an autoimmune disease that causes damage to the nervous 
system and causes tingling sensation, muscle weakness, and even paralysis (Table 2). In general, 
it manifests itself following vaccination with formulations containing viral vectors4 or, in this 
case, VLP (Viral-Like Particles) used in the currently marketed HPV vaccines. The POTS is 
also a syndrome that causes nerve damage, but it causes slightly milder symptoms such as 
palpitations, malaise, and dizziness (Table 2). In fact, some studies have shown a temporal 
association between vaccines and GBS/POTS24,25. However, the WHO reports that no serious 
adverse events have been reported even after its application to millions of people and that the 
occurrence of GBS in vaccinated persons has a frequency similar to cases of disease with an 
unknown cause41. The marketing of these vaccines continues to be released by ANVISA and 
the FDA, and any adverse effects must be reported to health agencies or to those responsible 
for the distribution and administration of the vaccines. 
Another vaccine formulation that deserves attention in relation to the possible occurrence of 
adverse events is the dengue vaccine, recently licensed for use in Brazil. Known as “CYD-TDV” 
or “Dengvaxia”, the vaccine is based on four attenuated virus strains of chimeric composition, 
that is, it consists of the yellow fever virus expressing envelope proteins of four DENV serotypes42. 
The formulation was submitted, in parallel, to two phase III clinical studies in Asian and Latin 
American countries (including Brazil), involving more than 30,000 participants aged between 
two and fourteen years (study “CYD14”) and nine to sixteen years (study “CYD15”) who received 
three doses43,44. The contraindications stipulated by the manufacturer are the same as those 
found for most attenuated vaccines and include individuals with allergies to any of the vaccine 
components (no adjuvants in the formulation), immunosuppressed individuals, and pregnant 
or lactating women. Local and systemic adverse events following immunization were similar 
to those reported by other live attenuated vaccines45.
However, the group of vaccinated individuals aged two to five years had a higher risk of 
hospitalization with severe forms of dengue compared to the placebo group of the same age group 
when infected with the wild virus in tests performed in Asia44. This event was observed mainly in 
the third year after the first dose and it was not observed in other age groups (6–8, 9–11, and 12–16 
years). In addition, an overall estimate against all serotypes of the virus resulted in a final efficacy of 
approximately 60% but an efficacy of 33.7% for the younger group (2–5 years)45. Such observations 
suggest that vaccination may contribute with an exacerbated secondary infection in very young 
seronegative children – a phenomenon known as ADE (Antibody Dependent Enhancement). 
In this phenomenon, viral replication is increased in individuals vaccinated or infected with viral 
strains other than those previously exposed, from the presence of non-neutralizing antibodies. 
Therefore, the vaccine was only indicated for children over nine years of age.
Table 2. Adverse events related to other vaccine components.
Component Function in the vaccine Vaccine Dose limit Adverse events studied References
Albumin (recombinant) Stabilizer Varicella/MMR 50 ng/dose Anaphylaxis 8
Antibiotics
To avoid contamination in 
the manufacturing process
Yellow fever, influenza, polio NA Allergic reactions 8
Formaldehyde/Glutaraldehyde 
To inactivate toxins 
or viral particles
Influenza
200 ppm 
(residual)
Eczema, cancer 8,29
Gelatin Stabilizer Yellow fever 10 µL/mL
Allergy, anaphylaxis, 
hypersensitivity
8,31,39
Egg proteins Virus cultivation Yellow fever, influenza NA Allergy, anaphylaxis 8,32
Sorbitol Stabilizer
Yellow fever, HPV, 
pneumococcal conjugate, polio
NA Intolerance, allergy 8
Thimerosal Preservative
DPT, MMR, Hepatitis B, 
influenza
0.01% or 25 
µg Hg/dose
Allergy, ASD 8,35–38,40
NA: Not applicable; ASD: Autism Spectrum Disorder; HPV: human papillomavirus 
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Risks Associated With Non-Vaccination
Among the risks related to vaccines, non-vaccination is considered the most important. 
The deleterious effects associated with the use of vaccines, when present and scientifically 
proved, occur at a very low frequency and are inexpressive when compared to risks related 
to non-vaccination. Strategies to stimulate the use of vaccines are traditionally adopted 
in public health, but they may be insufficient to ensure an increase in vaccine coverage. 
In this context, a clear understanding of the value of vaccines needs to be kept both in 
the population and among health professionals46. In Brazil, vaccination is mandatory and 
regulated by federal legislation (Decree 78,231, of August 12, 1976)47. 
However, the non-vaccination decision is individual and influenced by factors such as 
public health policies, recommendation of health professionals, media, and factors intrinsic 
to the individual, such as knowledge and information, past experiences, perception of the 
importance of vaccination, and moral and religious convictions. These factors are inserted 
in a historical, political, and social context that should also be considered48. However, the 
decision of the individual does not only affect him or her. The decision not to vaccinate or the 
persuasion of persons to avoid doing so contributes to reduce population immunity (or herd 
immunity), which may result in localized outbreaks or pockets of infection in specific groups 
or populations. This type of situation has assumed worrying proportions, especially since the 
1970s and 1980s, when cases of pertussis exponentially increased in developed countries, 
a disease that is easily controlled with adequate vaccination coverage49.
These outbreaks are becoming more frequent and may be related to several factors (Table 3). 
Most studies report individuals who individually decided not to vaccinate or who traveled 
or migrated from an environment with high vaccine coverage to another with low vaccine 
coverage, exposing unvaccinated populations to the pathogen. Because of this phenomenon, 
some diseases previously controlled by effective vaccination programs, such as measles, have 
resurfaced in populations from different parts of the world, including Brazil. 
Table 3. Scientific articles published between 2010-2016, which correlate outbreaks of infectious diseases to unvaccinated individuals and 
their respective reasons/sources of outbreaks.
Disease Country of outbreak (year)Outbreak Reason/Source References
Measles
Qatar (2007)a; China (2010)a; Norway (2011)a; Macedonia (2010–2011)a; Ireland (2009–2010)b; Poland and 
Greece (2010)b; Serbia (2010–2011)b; Spain (2012)b; Zimbabwe (2010)c; USA (2013)c; Netherlands (2013)c; 
Spain (2010-2011)c; USA (2009)d; Norway (2011)d; England (2013)d; USA (2011)e; Northern Ireland (2010)f; 
Spain (2010)f; Israel (2012)f; USA (2011, 2012, 2013)f; England (2008–2009)f; USA (2008, 2011)g; Italy (2008, 
2009, 2010)g; Spain (2011)g; China (2013)h; Democratic Republic of Congo (2010)h; Romania (2011)h; France 
(2008–2011)h; Brazil (2012–2013a, 2013–2015h)
54–86
Mumps
Canada (2008)g; USA (2011)g; Netherlands and Canada (2007–2009)c; USA (2009–2010)c; Bosnia Herzegovina 
(2010–2011)i; Mongolia (2011)h
87–92
Diphtheria Norway (2008)g 93
Rubella Romania (2011–2012)g; Japan (2012–2013)g; China (2010–2011)a 94,95
Pertussis Brazil (2004, 2007)h; USA (2009–2010)c; USA (2010, 2012)g; Italy (2009)h; Papua New Guinea (2011)j 96–102
Yellow fever Brazil (2008–2009h, 2015a); Angola and Democratic Republic of Congo (2015–2016)h 50–52,103
Poliomyelitis Somalia (2013)i 104
a Migration/Immigration of unvaccinated individuals.
b Gypsy communities.
c Orthodox communities.
d Unvaccinated health professionals.
e Refugees.
f Unvaccinated travelers.
g Individuals intentionally unvaccinated.
h Vaccination failures/Accumulation of unvaccinated persons.
i Armed conflicts.
j Geographical isolation. 
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In relation to yellow fever, more than 100 million persons were vaccinated in West Africa 
in 2015. However, Angola and the Democratic Republic of Congo had an outbreak of this 
disease between December 2015 and January 2016. Men accounted for approximately 70% 
of the cases50,51. Studies have related this outbreak to the high population density coupled 
with the low vaccination coverage of men. In the same year, nine fatal cases of yellow 
fever were reported, five in Brazil, all in non-vaccinated persons, but in situations with 
vaccination recommendation (tourism or residents of rural areas)52. According to the Center 
for Emergency Operations in Public Health (COES), 371 cases and 127 deaths were recorded 
from 2016 to March 2017. It is speculated the outbreak relation with the low vaccination 
coverage (with the inclusion of non-endemic regions) and some factors such as deforestation 
and environmental accidents in wildlife habitats, including non-human primate hosts. 
Measles has been considered as eliminated in the Americas since 2002, but it has a growing 
incidence in Brazil and the world, which is a reflection of voluntary non-vaccination. Between 
2013 and 2015, more than 1,000 cases were reported only in the states of Pernambuco and 
Ceará, affecting individuals aged between 15 and 29 years (34%) and infants under one year 
(27.5%) from the circulation of one virus type from Europe53,54. According to the WHO, the 
estimate is that immunization has prevented more than 20 million deaths between 2000 
and 2015 worldwide, making the measles vaccine one of the most effective in public health.
FINAL CONSIDERATIONS
The risks associated with the use of available vaccines do not justify discontinuation 
of any available formulation in the market. On the other hand, the risk associated with 
“non-vaccination” causes growing concerns in several countries. Advertising campaigns, 
disseminated in social media or even dressed in supposedly “scientific” evidence, contribute 
to the resurgence of diseases once eradicated in much of the world. In Brazil, in particular, 
lack of information and dissemination of unfounded information contribute to the 
reappearance of infectious diseases, such as measles and pertussis. We also highlight the 
risk associated with non-acceptance of vaccines, such as those involving the prevention 
of HPV infection, and we can only expect its impacts on mortality if adequate conditions 
of vaccine administration and coverage are kept. The role of health professionals in 
disseminating the benefits associated with vaccination is important to ensure the health 
and quality of life of the population.
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